- Clinical Trials
Our technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options.
We are developing gene therapies for patients with cancer and diabetes to bring new treatment options to large patient populations. Our lead product candidate, GPX-001, is designed to be administered in combination with other therapies, including targeted therapies and immunotherapies, for non-small cell lung cancer.
We have assembled a multidisciplinary team of executives and advisors with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.
At Genprex, we are committed to developing life-changing gene therapies for patients with cancer and diabetes through unique, innovative science. We are dedicated in our efforts to helping patients with limited or no treatment options to have access to new and advanced therapies to more effectively treat their disease.
Genprex was added to the Russell 3000® Index after the market closed on Friday, June 26, 2020 as part of the 2020 Russell U.S. Indexes reconstitution.
Company executes on corporate communication strategy and advances drug branding initiatives
Rodney Varner will be participating in a live interview with the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show, on Thursday, June 25.
Expansion enables full commercial scale plasmid DNA manufacturing capabilities
We’re passionate about the work we’re doing to revolutionize the fight against cancer and diabetes. Whether you or somebody you know is afflicted by one of these diseases, you are a medical practioner interested in our treatment options, or you are an investor that has supported our fight, we want to keep you informed of our advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.